Higher EMT/tumor/CSC marker abundance was significantly associated with the carboplatin responder group (Figure 4B) including protein markers Mesothelin, Nanog, STAT1, and E-Cadherin (Figure S2A). This evidence concerns the gene CDH1 and neoplasm.